Author Affiliation: RAND Corporation, Santa Monica, California, and School of Public Health, David Geffen School of Medicine, University of California, Los Angeles.
With substantial support across the political spectrum, the Obama administration has included in the American Recovery and Reinvestment Act more than $1 billion to support comparative effectiveness research.1 At the same time, the president has demanded reforms in the US health care system to make health care more affordable for all US citizens.2 This Commentary focuses on the interaction of these 2 initiatives: what will be the cost effect of spending $1 billion on comparative effectiveness research?
Brook RH. Possible Outcomes of Comparative Effectiveness Research. JAMA. 2009;302(2):194-195. doi:10.1001/jama.2009.996